



Press Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and COO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com>

Daiichi Sankyo Announces New Oxycodone Tablets "Daiichi Sankyo" for Cancer Pain Treatment in Japan

Tokyo, Japan (August 28, 2017) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new generic oxycodone immediate release formulation for cancer pain treatment: Oxycodone Tablets 2.5 mg, 5 mg, 10 mg and 20 mg “Daiichi Sankyo” in Japan (date of marketing approval: February 15, 2017; date of listing in the NHI reimbursement price list in Japan: June 16, 2017).

Oxycodone Tablets “Daiichi Sankyo” are the first generic immediate release tablets containing oxycodone hydrochloride, a strong opioid analgesic providing moderate to severe pain relief which can be prescribed for various types of cancer. The tablets are small and easy to take, and are consistently manufactured from drug substance to formulation by Daiichi Sankyo’s domestic subsidiary, Daiichi Sankyo Propharma Co., Ltd. (marketing authorization holder).

Daiichi Sankyo expects that Oxycodone Tablets “Daiichi Sankyo” will help to expand our product lineup of opioid analgesics and offer a novel treatment option to cancer patients and healthcare providers in Japan.

Product Summary

Product Name	Therapeutic Category	Original Brand Name
Oxycodone Tablets 2.5 mg “Daiichi Sankyo”	Cancer pain treatment	OxiNorm® Powder 2.5 mg
Oxycodone Tablets 5 mg “Daiichi Sankyo”		OxiNorm® Powder 5 mg
Oxycodone Tablets 10 mg “Daiichi Sankyo”		OxiNorm® Powder 10 mg
Oxycodone Tablets 20 mg “Daiichi Sankyo”		OxiNorm® Powder 20 mg

About Daiichi Sankyo Opioid Analgesics in Japan

Daiichi Sankyo believes that expanding our product lineup of opioid analgesics helps patients with cancer to improve their quality of life by relieving pain and contributes to the total care for the life of patients with cancer. Daiichi Sankyo launched Oxycodone Extended Release Tablets "Daiichi Sankyo" for cancer pain relief in March 2017. In June 2017, Daiichi Sankyo also launched hydromorphone hydrochloride Narurapid® Tablets (immediate release formulation) and Narusus® Tablets (once-daily extended release formulation), and is applying for NDA approval of hydromorphone hydrochloride injection.

Daiichi Sankyo collaborates with Kyukyu Pharmaceutical Co., Ltd. to commercialize generic transdermal fentanyl citrate patches for long-acting cancer pain relief.